iShares China Large-Cap ETF vs 22nd Century Group Inc — how do they compare? iShares China Large-Cap ETF trades at $34.53, while 22nd Century Group Inc trades at $4.33 (market cap $1.52M). Which is the better fit depends on your goals.
| FXI | XXII | |
|---|---|---|
52-Week High | $41.75 | $1.47K |
52-Week Low | $31.59 | $3.90 |
Market Cap | — | $1.52M |
Sector | — | Technology |
Enterprise Value | — | -$6.71M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
22nd Century Group (XXII) trades at $4.33, up 3.34% on the day, following a recent 20:1 reverse stock split. The stock shows a bearish technical signal with support at $4 and resistance at $5. Fundamentally, the company continues to operate at a loss with negative gross and net profit margins, though revenue reached $7.05M in 2025. Recent news highlights aggressive expansion of its VLN reduced-nicotine cigarette brand into California and New York markets.
The outlook remains speculative with significant execution risk. While analyst consensus is strongly bullish (75% buy ratings), the company must demonstrate a path to profitability through its VLN product expansion. Key risks include persistent cash burn, competitive tobacco market pressures, and regulatory uncertainty. The stock represents a high-risk, high-potential turnaround play dependent on commercial success of its reduced-nicotine platform.
Trailing returns across standard periods
Latest headlines on both assets
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →